Mumbai-based pharmaceutical company Rubicon Research Ltd received one procedural US FDA Form 483 observation following an unannounced inspection of its manufacturing facility at J4/2, Additional MIDC, Satara - 415 004, Maharashtra, India from Monday, October 5 to Friday, October 9, 2026. According to reports from Can Fin Homes, the company stated that the observation is procedural in nature and does not relate to data integrity. Rubicon Research expressed confidence in working closely with the regulator to successfully conclude the evaluation in a timely manner.
As reported by Can Fin Homes, the Satara inspection represents the third successful unannounced US FDA inspection in financial year 2026-27, following inspections of the company's Toronto research and development facility in Canada in April 2026 and its Pithampur manufacturing facility in India in July 2026. The company's previous US FDA inspection at the Satara facility took place in January 2023, with prior intimation provided to the company. A successful outcome for the Satara facility would mark the first successful unannounced US FDA inspection of this site, building on the company's track record of regulatory compliance.
According to Can Fin Homes, the company's recently acquired manufacturing facility in East Brunswick, New Jersey, in the United States, was inspected by the US FDA in May 2026, just prior to the company acquiring the facility in July 2026. This inspection was completed before the facility became part of Rubicon Research's portfolio, demonstrating the company's commitment to regulatory compliance across all facilities.
As reported by Can Fin Homes, Rubicon Research Limited shares were trading at ₹1,546.60 on the BSE as of the latest trading session, compared to the previous close of ₹1,533.70. The stock demonstrated active trading with 7,706 shares traded across 744 trades during the session. The stock hit an intraday high of ₹1,551.80 and an intraday low of ₹1,505.80, with a net turnover of ₹117.50 lakh. The positive market response reflects investor confidence in the company's regulatory compliance and successful inspection outcomes.
